Selected article for: "corona virus and novel corona virus"
Author: Gulati, Shuchi; Muddasani, Ramya; Bergerot, Paulo; Pal, Sumanta Kumar
Title: Systemic therapy and COVID19: Immunotherapy and Chemotherapy
  • Cord-id: 2e31a5b6
  • Document date: 2020_12_26
    • ID: 2e31a5b6
    Snippet: As the novel severe acute respiratory syndrome coronavirus-2 related pandemic- Corona Virus Disease 2019 (COVID-19) has emerged, decision making in the context of cancer treatment has become more complex. The apprehension of using drugs that could adversely affect infected patients, the risk of not using life-saving treatments and the complexities related to the type of cancer itself, all must be taken into consideration before proceeding with treatment. Data from large registries such as COVID-
    Document: As the novel severe acute respiratory syndrome coronavirus-2 related pandemic- Corona Virus Disease 2019 (COVID-19) has emerged, decision making in the context of cancer treatment has become more complex. The apprehension of using drugs that could adversely affect infected patients, the risk of not using life-saving treatments and the complexities related to the type of cancer itself, all must be taken into consideration before proceeding with treatment. Data from large registries such as COVID-19 and Cancer Consortium (CCC19), Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) and NCI COVID-19 in Cancer Patients Study (N-CCaPS) will hopefully provide granularity on the outcomes of patients with cancer who are infected with COVID-19. As these efforts are underway, this review aims to shed light on the management of patients with genitourinary malignancies being treated with systemic therapies while infected with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • academic medical center study and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • active cancer and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active cancer and locally advanced: 1, 2
    • acute respiratory syndrome and adequate immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory syndrome and adequate immune response mount: 1, 2, 3
    • acute respiratory syndrome and administration require: 1, 2, 3, 4, 5
    • acute respiratory syndrome and locally advanced: 1